The medical website says the country is in for a bad allergy season.
Preliminary documents suggest a positive view for the under-the-tongue medication.
User fees keep the regulator's review process running for some drugs, while others see review dates slip.
The EpiPen manufacturer's latest effort: an e-book that shows children making allergy-friendly swaps at a school event.
Sanofi may make OTC history; Celgene joins a new collaboration; and the US Task Force of Preventative Medicine wants to make lung cancer screening the norm
With its recent actions on sleep aids and allergy medications, the FDA is demonstrating growing concern about the effects of prescription drugs on driving. One CRO is fielding a fleet of driving simulators to help manufacturers salve the agency's worries.
The company's latest outreach, an Auvi-Q promotion, breaks down allergy management into sports playbook presentation.
Emmy-winner Julie Bowen is part of the effort to spread allergy education and awareness in schools.
The drugmaker's new auto-injecting epinephrine pen provides verbal cues during emergency allergic situations. It's the latest entry in a competitive market.
Mylan's Dey Pharma launched MyEpiPen App, designed to help patients with severe allergies and their caregivers cope with episodes of anaphylaxis.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Lawmakers propose allowing pharma companies to share some off-label information
- US pharma market value projected to be $550 billion in five years
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Apple's ResearchKit: Five Guidelines for Pharma